3,389 press releases indexed under healthcare.
Pilot Combines Clinician Guided Phenotypes with IMO Health's Unique Terminology Identifiers to Help Clinicians Easily Identify Patients Most Likely to Benefit from Pivot Insulin Pump Therapy Advancing Towards Fourth Quarter Commercial Launch of Pivot Pump
FDA-cleared, non-invasive, drug-free technology now available to VA and federal healthcare providers, supported by education, demonstration, onboarding, and implementation resources for clinic-to-home use.
Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612 ).
STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe.
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan
Funding Positions Company for Commercial Launch of XenFi™, Continued Innovation of Wireless Medical Devices and Technologies and its AI-Enabled Physical Intelligence™ Platform Expands Board of Directors with Appointment of Financial Executive Linda Vega DRAPER, Utah, July 16, 2026...
SOUTH SURREY, British Columbia, July 16, 2026 (SEND2PRESS NEWSWIRE) -- Author Corinne Brown releases her deeply personal memoir, "Me, Mom & the Monster: Our Dance Through Huntington's Disease," a powerful and intimate account of one family's experience living with a devastating genetic illness. ISBN: 978-1834383958, released June 2, 2026 by Tellwell Publishing.
Expanding access to safe, personalized medical weight loss for Iowa teens through convenient telemedicine, experienced physician, and customized treatment plans designed for long-term success. The post California Trim Clinic Expands Teen Medical Weight Loss Program to Iowa first appeared on